Abstract: The present disclosure relates to an LED active luminous traffic marking based on light-transmitting concrete and a construction method thereof. The luminous traffic marking includes a light-transmitting concrete layer and a light source layer that are arranged vertically, where the light-transmitting concrete layer includes a concrete base and a plurality of light-guide fibers embedded in the concrete base, the light source layer includes an integrated LED light source board and a packaging protective shell for packaging the integrated LED light source board, the packaging protective shell is a shell with anchoring hollow protrusions, and the packaging protective shell is anchored to the concrete base through the anchoring hollow protrusions. Compared with the prior art, the present disclosure improves the visibility, digitalization and intelligence level of road traffic markings, and has a broad application prospect.

Abstract: The present disclosure relates to an LED active luminous traffic marking based on light-transmitting concrete and a construction method thereof. The luminous traffic marking includes a light-transmitting concrete layer and a light source layer that are arranged vertically, where the light-transmitting concrete layer includes a concrete base and a plurality of light-guide fibers embedded in the concrete base, the light source layer includes an integrated LED light source board and a packaging protective shell for packaging the integrated LED light source board, the packaging protective shell is a shell with anchoring hollow protrusions, and the packaging protective shell is anchored to the concrete base through the anchoring hollow protrusions. Compared with the prior art, the present disclosure improves the visibility, digitalization and intelligence level of road traffic markings, and has a broad application prospect.

Abstract: Disclosed is a stent with a drug coating for preventing and treating restenosis, comprising a stent and a drug coating covering the surface of the stent. The active ingredients in the drug coating are guaiane sesquiterpene compounds P1, P2 and P3. P1 is Zedoalactone B, P2 is a stereoisomer of P1, and P3 is Zedoarondiol. Compared with an existing sirolimus eluting stent, the present drug eluting stent can inhibit the intimal hyperplasia and the inflammatory reactions of vascular walls, and promote the endothelialization of blood vessels after the stent is implanted, and thus can prevent the long-term thrombotic complications; and has the advantages of small dosage, low cost, and no toxic side effect.

Abstract: Disclosed is a stent with a drug coating for preventing and treating restenosis, comprising, a stent and a drug coating covering the surface of the stent. The active ingredients in the drug coating are guaiane sesquiterpene compounds P1, P2 and P3. P1 is Zedoalactone B, P2 is a stereoisomer of P1, and P3 is Zedoarondiol. Compared with an existing sirolimus eluting stent, the present drug eluting stent can inhibit the intimal hyperplasia and the inflammatory reactions of vascular walls, and promote the endothelialization of blood vessels after the stent is implanted, and thus can prevent the long-term thrombotic complications; and has the advantages of small dosage, low cost, and no toxic side effect.